Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

PROCEPT BioRobotics (PRCT) Shares Outstanding (2020 - 2026)

PROCEPT BioRobotics has reported Shares Outstanding over the past 7 years, most recently at $56.9 million for Q1 2026.

  • Quarterly Shares Outstanding rose 2.93% to $56.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $56.9 million through Mar 2026, up 2.93% year-over-year, with the annual reading at $56.3 million for FY2025, 2.93% up from the prior year.
  • Shares Outstanding was $56.9 million for Q1 2026 at PROCEPT BioRobotics, up from $56.3 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $56.9 million in Q1 2026 and troughed at $44.1 million in Q1 2022.
  • The 5-year median for Shares Outstanding is $51.4 million (2024), against an average of $50.6 million.
  • Year-over-year, Shares Outstanding soared 744.87% in 2022 and then grew 1.65% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $44.8 million in 2022, then increased by 13.26% to $50.8 million in 2023, then rose by 7.77% to $54.7 million in 2024, then rose by 2.93% to $56.3 million in 2025, then rose by 1.02% to $56.9 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Shares Outstanding are $56.9 million (Q1 2026), $56.3 million (Q4 2025), and $55.9 million (Q3 2025).